---
title: "Entyvio (vedolizumab) in ulcerative colitis: Dosing and administration questions"
description: "Dosing and administration questions on Entyvio (vedolizumab) in ulcerative colitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Premedication, Treatment combinations, Dosing, Switching, Administration, and Preparation. Questions: Was premedication used for Entyvio infusion reactions in clinical trials? Can Entyvio be used with steroids or immunomodulators? What is the Entyvio dosing schedule for ulcerative colitis? Is Entyvio IV every 4 weeks more effective than every 8 weeks? 6 further questions follow. 10 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab) in ulcerative colitis: Dosing and administration questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)

Questions that apply to every indication of Entyvio are on [Entyvio (vedolizumab), all indications](https://www.evicenter.com/medical-information/entyvio).

## Premedication

<a id="entyvio-infusion-premedication"></a>

### Was premedication used for Entyvio infusion reactions in clinical trials?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “In clinical trials, for patients with mild IRRs or hypersensitivity reactions, physicians were 
> allowed to pretreat with standard medical treatment (e.g., antihistamine, hydrocortisone, 
> and/or acetaminophen) prior to next infusion.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

## Treatment combinations

<a id="entyvio-with-steroids-immunomodulators"></a>

### Can Entyvio be used with steroids or immunomodulators?

> “ENTYVIO IV can be administered concomitantly with aminosalicylates, steroids, or immunomodulators.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) IV Administration and Dosing, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/iv#accordion-1d21186105-item-56090e0392:~:text=ENTYVIO%20IV%20can%20be%20administered%20concomitantly%20with%20aminosalicylates%2C%20steroids%2C%20or%20immunomodulators.)

> “ENTYVIO SC can be administered concomitantly with  aminosalicylates, steroids, and  immunomodulators.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Pen Prescribing & Dosing Guide, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/pen#accordion-d10b53ff15-item-779ac4d2a0:~:text=ENTYVIO%20SC%20can%20be%20administered%20concomitantly%20with%20aminosalicylates%2C%20steroids%2C%20and%20immunomodulators.)

## Dosing

<a id="entyvio-dosing"></a>

### What is the Entyvio dosing schedule for ulcerative colitis?

> “•• Week 0: Administer ENTYVIO 300 mg by intravenous infusion over approximately 
> 30 minutes [see Dosage and Administration (2.3)].
> •• Week 2: Administer ENTYVIO 300 mg by intravenous infusion over approximately 
> 30 minutes.
> •• Week 6: Patients may remain on ENTYVIO intravenous therapy or switch to 
> subcutaneous injection after receiving two ENTYVIO intravenous doses administered 
> at Week 0 and Week 2.
> °° Intravenous Infusion: Administer ENTYVIO 300 mg by intravenous infusion 
> over approximately 30 minutes and then every eight weeks thereafter.
> °° Subcutaneous Injection: Administer ENTYVIO 108 mg subcutaneously once 
> every 2 weeks.
> •• Discontinue therapy in patients who show no evidence of therapeutic benefit by 
> Week 14.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

<a id="entyvio-every-4-weeks"></a>

### Is Entyvio IV every 4 weeks more effective than every 8 weeks?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “The ENTYVIO every four week dosing regimen did not demonstrate additional clinical benefit 
> over the every eight dosing week regimen. The every four week dosing regimen is not the 
> recommended dosing regimen [see Dosage and Administration (2.2)].”

Source: [ENTYVIO: Prescribing information, page 6, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=6)

Note: This result is from the ulcerative colitis maintenance trial (UC Trial II).

<a id="entyvio-missed-dose"></a>

### What should be done if an Entyvio Pen dose is missed?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “If treatment with subcutaneous ENTYVIO is interrupted or if a scheduled dose(s) of 
> subcutaneous ENTYVIO is missed, inject the next subcutaneous dose as soon as 
> possible and then every 2 weeks thereafter.
> In the event of incomplete dose administration (i.e., patient attempts administration 
> of dose with ENTYVIO PEN, however it is uncertain if a full dose was administered), 
> instruct the patient to call their pharmacy or healthcare provider.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

## Switching

<a id="entyvio-switch-iv-to-pen"></a>

### Can patients switch from Entyvio IV to the Entyvio Pen?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “Patients currently receiving and responding to ENTYVIO intravenous therapy after Week 6 
> may also be switched to subcutaneous injection. Administer the first subcutaneous dose in 
> place of the next scheduled intravenous infusion and every two weeks thereafter.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

> “The efficacy and safety of switching from ENTYVIO SC to ENTYVIO IV have not been studied.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Pen Prescribing & Dosing Guide, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/pen#accordion-d10b53ff15-item-779ac4d2a0:~:text=The%20efficacy%20and%20safety%20of,IV%20have%20not%20been%20studied.)

> “To transition patients to ENTYVIO SC, start the pharmacy benefit PA process 2-4 weeks before the next scheduled infusion date.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Pen Prescribing & Dosing Guide, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/pen#accordion-d10b53ff15-item-779ac4d2a0:~:text=To%20transition%20patients%20to%20ENTYVIO,the%20next%20scheduled%20infusion%20date.)

## Administration

<a id="entyvio-infusion-time"></a>

### How long does an Entyvio IV infusion take?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “ENTYVIO is administered as a 300 mg flat dose over an approximately 30-minute IV infusion.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) IV Administration and Dosing, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/iv#accordion-1d21186105-item-56090e0392:~:text=ENTYVIO%20is%20administered%20as%20a,an%20approximately%2030%2Dminute%20IV%20infusion.)

> “Approximately
> 30 minutes
> Per infusion
>
> Plus monitoring time
>
> 6 infusions
> Per year
>
> 8 infusions in year 1”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) IV Administration and Dosing, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/iv#accordion-1d21186105-item-56090e0392:~:text=Approximately,8%20infusions%20in%20year%201)

> “ENTYVIO IV should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use. Observe patients during infusion and until the infusion is complete.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) IV Administration and Dosing, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/iv#accordion-1d21186105-item-56090e0392:~:text=ENTYVIO%20IV%20should%20be%20administered,until%20the%20infusion%20is%20complete.)

<a id="entyvio-self-injection"></a>

### Can patients inject the Entyvio Pen themselves at home?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “•• ENTYVIO prefilled syringe and ENTYVIO PEN are intended for subcutaneous use 
> under the guidance and supervision of a healthcare professional.
> •• Patients may self-inject or caregivers may inject subcutaneous ENTYVIO using 
> either the ENTYVIO prefilled syringe or ENTYVIO PEN after training in subcutaneous 
> injection technique. Provide proper training to patients and/or caregivers on the 
> subcutaneous injection technique of ENTYVIO.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

> “After proper training on correct subcutaneous injection technique, a patient or caregiver may administer the ENTYVIO Pen if a healthcare professional determines it is appropriate. Patients and caregivers should be instructed to follow the directions for administration of the ENTYVIO Pen in the Instructions For Use section of the Full Prescribing Information.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Pen Prescribing & Dosing Guide, captured 2026-11-13](https://www.entyviohcp.com/dosing-administration/pen#accordion-d10b53ff15-item-779ac4d2a0:~:text=After%20proper%20training%20on%20correct,of%20the%20Full%20Prescribing%20Information.)

<a id="entyvio-injection-sites"></a>

### Where should the Entyvio Pen be injected?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “•• Administer each subcutaneous injection at a different anatomic location (such 
> as thighs, any quadrant of abdomen, or upper arms) than the previous injection. 
> Administration of ENTYVIO in the back of upper arm may only be performed by a 
> healthcare professional or caregiver. Do not inject into moles, scars, bruises, or areas 
> where the skin is tender, erythematous, or indurated.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

## Preparation

<a id="entyvio-iv-preparation"></a>

### How is Entyvio IV reconstituted and diluted?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “Reconstitution Instructions
> 1.	Remove the flip-off cap from the single-dose vial and wipe with alcohol swab. 
> Reconstitute ENTYVIO vial containing lyophilized powder with 4.8 mL of Sterile 
> Water for injection, 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection, 
> at room temperature (20°C to 25°C [68°F to 77°F]), using a syringe with a 21- to 
> 25-gauge needle.
> 2.	Insert the syringe needle into the vial through the center of the stopper and direct the 
> stream of Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Lactated 
> Ringer’s Injection, to the glass wall of the vial to avoid excessive foaming.
> 3.	Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder.
> Do not vigorously shake or invert.
> 4.	Allow the solution to sit for up to 20 minutes at room temperature to allow for 
> reconstitution and for any foam to settle; the vial can be swirled and inspected for 
> dissolution during this time. If not fully dissolved after 20 minutes, allow another 
> 10 minutes for dissolution. Do not use the vial if the drug product is not dissolved 
> within 30 minutes.
> 5.	Visually inspect the reconstituted ENTYVIO solution for particulate matter and 
> discoloration prior to dilution. Solution should be clear or opalescent, colorless 
> to light brownish yellow and free of visible particulates. Do not administer 
> reconstituted solution showing uncharacteristic color or containing particulates.
> 6.	Once dissolved, gently invert vial three times.
> 7.	Immediately, withdraw 5 mL (300 mg) of reconstituted ENTYVIO solution using 
> a syringe with a 21- to 25-gauge needle. Discard any remaining portion of the 
> reconstituted solution in the vial.
> Dilution Instructions
> Add the 5 mL (300 mg) of reconstituted ENTYVIO solution to 250 mL of 0.9% Sodium 
> Chloride Injection, or Lactated Ringer’s Injection, and gently mix the infusion bag. Do not 
> add other medicinal products to the prepared infusion solution or intravenous infusion set. 
> Once reconstituted and diluted, use the infusion solution as soon as possible.
> Discard any unused portion of the infusion solution.”

Source: [ENTYVIO: Prescribing information, page 2, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=2)

## Related pages
- [Medical information: Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)
- [Indication](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/safety)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/guidelines)
